Keith Pagnani, Co-head of S&C’s Healthcare & Life Sciences practice, appeared on “Capital Forum” to discusses the challenges and opportunities impacting medtech M&A with Stryker Chairman & CEO Kevin Lobo and Capital Forum host Jack Kalavritinos.
Keith said he’s optimistic that medtech M&A will rebound despite a recent slowdown. “M&A is always going to be in the toolbox,” he said. “If history is any indication, at the end of this cycle we’re going to see more tuck-in transactions, more divestiture of non-core assets and a focus on the core business,” Keith noted. “Over the long term I’m optimistic.”
S&C is a sponsor of the MedTech Conference, which will take place in Boston from October 24 to 26. Learn more and register here.
Watch Keith’s discussion of headwinds and opportunities in medtech M&A:
Sullivan & Cromwell’s Healthcare M&A Group
S&C’s Healthcare & Life Sciences Group has been at the forefront of healthcare M&A activity, bringing its creativity, culture of collaboration and deal prowess to advise an assortment of clients across the healthcare industry on some of the biggest and most significant matters.